462 related articles for article (PubMed ID: 25391693)
1. The role of the LRRK2 gene in Parkinsonism.
Li JQ; Tan L; Yu JT
Mol Neurodegener; 2014 Nov; 9():47. PubMed ID: 25391693
[TBL] [Abstract][Full Text] [Related]
2. Co-occurrence of sporadic parkinsonism and late-onset Alzheimer's disease in a Brazilian male with the LRRK2 p.G2019S mutation.
Santos-Rebouças CB; Abdalla CB; Baldi FJ; Martins PA; Corrêa JC; Gonçalves AP; Cunha MS; Borges MB; Pereira JS; Laks J; Pimentel MM
Genet Test; 2008 Dec; 12(4):471-3. PubMed ID: 19072560
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, alpha-synuclein, and tau.
Taymans JM; Cookson MR
Bioessays; 2010 Mar; 32(3):227-235. PubMed ID: 20127702
[TBL] [Abstract][Full Text] [Related]
4. Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration.
Gaig C; Ezquerra M; Martí MJ; Valldeoriola F; Muñoz E; Lladó A; Rey MJ; Cardozo A; Molinuevo JL; Tolosa E
J Neurol Sci; 2008 Jul; 270(1-2):94-8. PubMed ID: 18353371
[TBL] [Abstract][Full Text] [Related]
5. The familial Parkinsonism gene LRRK2 regulates neurite process morphology.
MacLeod D; Dowman J; Hammond R; Leete T; Inoue K; Abeliovich A
Neuron; 2006 Nov; 52(4):587-93. PubMed ID: 17114044
[TBL] [Abstract][Full Text] [Related]
6. Analysis of 14 LRRK2 mutations in Parkinson's plus syndromes and late-onset Parkinson's disease.
Tan EK; Skipper L; Chua E; Wong MC; Pavanni R; Bonnard C; Kolatkar P; Liu JJ
Mov Disord; 2006 Jul; 21(7):997-1001. PubMed ID: 16602113
[TBL] [Abstract][Full Text] [Related]
7. Clinical genetics of Parkinson's disease and related disorders.
Wider C; Wszolek ZK
Parkinsonism Relat Disord; 2007; 13 Suppl 3():S229-32. PubMed ID: 18267241
[TBL] [Abstract][Full Text] [Related]
8. Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain.
Higashi S; Biskup S; West AB; Trinkaus D; Dawson VL; Faull RL; Waldvogel HJ; Arai H; Dawson TM; Moore DJ; Emson PC
Brain Res; 2007 Jun; 1155():208-19. PubMed ID: 17512502
[TBL] [Abstract][Full Text] [Related]
9. Olfactory heterogeneity in LRRK2 related Parkinsonism.
Silveira-Moriyama L; Munhoz RP; de J Carvalho M; Raskin S; Rogaeva E; de C Aguiar P; Bressan RA; Felicio AC; Barsottini OG; Andrade LA; Chien HF; Bonifati V; Barbosa ER; Teive HA; Lees AJ
Mov Disord; 2010 Dec; 25(16):2879-83. PubMed ID: 20818658
[TBL] [Abstract][Full Text] [Related]
10. Clinical implications of gene discovery in Parkinson's disease and parkinsonism.
Wider C; Foroud T; Wszolek ZK
Mov Disord; 2010; 25 Suppl 1():S15-20. PubMed ID: 20187245
[TBL] [Abstract][Full Text] [Related]
11. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
[TBL] [Abstract][Full Text] [Related]
12. [Clinical molecular genetics for PARK8 (LRRK2)].
Tomiyama H; Hatano T; Hattori N
Brain Nerve; 2007 Aug; 59(8):839-50. PubMed ID: 17713120
[TBL] [Abstract][Full Text] [Related]
13. Parkinsonism, Lrrk2 G2019S, and tau neuropathology.
Rajput A; Dickson DW; Robinson CA; Ross OA; Dächsel JC; Lincoln SJ; Cobb SA; Rajput ML; Farrer MJ
Neurology; 2006 Oct; 67(8):1506-8. PubMed ID: 17060589
[TBL] [Abstract][Full Text] [Related]
14. LRRK2 in Parkinson's disease: protein domains and functional insights.
Mata IF; Wedemeyer WJ; Farrer MJ; Taylor JP; Gallo KA
Trends Neurosci; 2006 May; 29(5):286-93. PubMed ID: 16616379
[TBL] [Abstract][Full Text] [Related]
15. Mendelian forms of Parkinson's disease.
Gasser T
Biochim Biophys Acta; 2009 Jul; 1792(7):587-96. PubMed ID: 19168133
[TBL] [Abstract][Full Text] [Related]
16. Homozygous mutation of the LRRK2 ROC domain as a novel genetic model of parkinsonism.
Chen ML; Wu RM
J Biomed Sci; 2022 Aug; 29(1):60. PubMed ID: 35965315
[TBL] [Abstract][Full Text] [Related]
17. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).
Kethiri RR; Bakthavatchalam R
Expert Opin Ther Pat; 2014 Jul; 24(7):745-57. PubMed ID: 24918198
[TBL] [Abstract][Full Text] [Related]
18. Novel insights into the neurobiology underlying LRRK2-linked Parkinson's disease.
Gómez-Suaga P; Fdez E; Fernández B; Martínez-Salvador M; Blanca Ramírez M; Madero-Pérez J; Rivero-Ríos P; Fuentes JM; Hilfiker S
Neuropharmacology; 2014 Oct; 85():45-56. PubMed ID: 24863040
[TBL] [Abstract][Full Text] [Related]
19. Subthalamic nucleus stimulation is efficacious in patients with Parkinsonism and LRRK2 mutations.
Schüpbach M; Lohmann E; Anheim M; Lesage S; Czernecki V; Yaici S; Worbe Y; Charles P; Welter ML; Pollak P; Dürr A; Agid Y; Brice A
Mov Disord; 2007 Jan; 22(1):119-22. PubMed ID: 17080443
[TBL] [Abstract][Full Text] [Related]
20. [Molecular basis of Parkinson's disease linked with mutations in the LRRK2 gene].
Pchelina SN; emel'ianov AK; Usenko TS
Mol Biol (Mosk); 2014; 48(1):3-14. PubMed ID: 25842821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
